Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01289483
Other study ID # 10-808
Secondary ID
Status Withdrawn
Phase N/A
First received January 31, 2011
Last updated April 17, 2017
Start date February 2011
Est. completion date April 2011

Study information

Verified date April 2017
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients scheduled for awake fiberoptic intubation (AFI) because of potential difficult airway will be consented prior to intubation ASA Physical Status classification and history of difficult intubation will be recorded at screening. The investigators will also record the results of airway examination including Mallampati classification, thyromental distance, mouth opening, neck circumference, neck range of motion, presence or absence of beard and overbite, history of neck radiation, and mandibular protrusion test Informed consent will be obtained prior to the procedure from those patients who meet the inclusion and exclusion criteria.

Standard hemodynamic monitoring will be used in all patients including EKG, blood pressure, heart rate, respiratory rate and oxygen saturation. Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale will be used to assess the level of alertness/sedation. Two consecutive MOAA/S scores of 4 will be considered as the desired effect of moderate sedation.

For AFI procedure, IV will be started and oxygen will be administered. 4 L of oxygen will be delivered through nasal canula until the completion of the AFI procedure. Patient head will be positioned in the sniffing position, Topical anesthesia would be achieved using the topical administration of 4 percent lidocaine using atomized and MaDgic nebulizer, and 2% xylocaine Jel applied to the surface of Williams airway in a total dose of lidocaine not exceeding 10 mg/kg. Patients will be randomized to one of the four fospropofol treatment arms: 2, 3.5, 5, or 6.5 mg/kg


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria:

- Age: between 18-64 years of age

- ASA physical status 1-3 ( Except patients with severe cardiac and/or pulmonary disease

- Weight 60-90 Kg

- Elective surgery requiring awake FOI

- Male or female, female patients should not be pregnant (documented by morning of surgery urine pregnancy test result as per routine hospital policy) or lactating

Exclusion Criteria:

- Previous exposure to any experimental drug within 30 days prior to study drug administration

- Raised intracranial pressure

- Patients for whom propofol is contraindicated

- Allergy to midazolam and/or fentanyl

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
fospropofol
After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
fospropofol
After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
fospropofol
After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
fospropofol
After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (2)

Lead Sponsor Collaborator
The Cleveland Clinic Eisai Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rescue intubation needed Requiring rescue midazolam and or fentanyl to facilitate intubation every 4 minutes during procedure, day 1
Primary Hypotension Development of hypotension ( defined as blood pressure drop of more than >30 % of base line) and/or hypoxemia ( SaO2 < 90% or a drop of >5% of baseline , whichever is lower) every 2 minutes, during procedure, day 1
Secondary hypertension Development of hypertension ( increase in blood pressure of > 30% of baseline), and/or tachycardia (120 beat/min or increase in heart rate of > 30% of base line, whichever is higher ) every 2 minutes, during procedure day 1
Secondary Total dose of midazolam and fentanyl used Total dose of midazolam and fentanyl used end of procedure, day 1
Secondary ease of intubation anesthesiologists' assessment of ease of intubation on a visual analog scale (VAS) of 0-10, with 0 being very easy, and 10 being very difficult. seconds, after intubation, day 1
Secondary Patient recall and satisfaction Patient recall and satisfaction end of procedure,day 1
Secondary Time to intubate Time to intubation ( first fospropofol bolus to positive EtCO2 ) seconds, during procedure, day 1
Secondary Failed intubation Failed intubation seconds, day 1
Secondary unresponsiveness Patient becoming un-responsive and /or requiring bag-mask Ventilation seconds, during procedure, day 1